Skip to main content

Table 2 Treatment characteristics and clinical outcomes

From: Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment

Characteristics

All patients, n = 75

Tumor budding

p

Low-intermediate, n = 29

High, n = 46

Adjuvant chemotherapy, N (%)

FUFA

11 (14)

2 (6)

9 (19)

0.2

Capecitabine

8 (10)

5 (17)

3 (6)

Folfox

23 (30)

8 (28)

15 (33)

Xelox

36 (46)

14 (49)

19 (42)

Relapse, N (%)

Yes

41 (55)

8 (28)

33 (72)

0.00

No

34 (45)

21 (72)

13 (28)

Relapse pattern, N (%)

Local

17 (41)

4 (50)

13 (39)

0.9

Visceral

24 (59)

4 (50)

20 (61)

KRAS status, N = 41 (%)

Wild

9 (22)

3 (38)

6 (18)

0.3

Mutant

32 (78)

5 (62)

27 (82)

NRAS status, N = 9 (%)

Wild

8 (89)

2 (67)

6 (100)

0.6

Mutant

1 (11)

1 (33)

0 (0)

BRAF status, N = 9(%)

Wild

8 (89)

2 (67)

6 (100)

0.6

Mutant

1 (11)

1 (33)

0 (0)

Disease-free survival

Median (months)

30

43

28

0.01

1 year (%)

89

93

86

3 years (%)

35

61

24